Literature DB >> 10501313

Molecular mechanisms of resistance to commonly used non-betalactam drugs in Streptococcus pneumoniae.

C A Widdowson1, K P Klugman.   

Abstract

This article reviews the molecular mechanisms of resistance to fluoroquinolones, erythromycin, chloramphenicol, tetracycline, and trimethoprim-sulfamethoxazole in Streptococcus pneumoniae. Resistance to fluoroquinolones primarily involves mutations in the DNA gyrase gene, gyrA, and in the topoisomerase IV genes, parC and parE, although in vitro studies have indicated that some strains may use an efflux mechanism for resistance to certain fluoroquinolones. Ciprofloxacin resistance results from initial and necessary mutations in ParC leading to low-level resistance and subsequent mutations in GyrA leading to high-level resistance. Sparfloxacin resistance results from initial mutations in GyrA, with ParC mutations occurring subsequently. A single amino acid substitution in ParE has also been associated with low-level resistance in S pneumoniae. Two mechanisms have been described for resistance to erythromycin. Coresistance to macrolides, lincosamides, and streptogramin B type antibiotics is a result of modification of the ribosome through methylation of an adenine residue in domain V of the 23S rRNA. This methylation is encoded by the methylase gene, ermAM. Resistance only to 14-and 15-membered macrolides is a result of efflux of the antibiotic from the cell, encoded by the gene, mefE, in S pneumoniae, and appears to be rapidly emerging as the predominant mechanism of resistance to erythromycin in many countries. The production of chloramphenicol acetyltransferase, an enzyme capable of catalyzing the conversion of chloramphenicol to its nonfunctional 1-acetoxy, 3-acetoxy, and 1,3-diacetoxy derivatives, leads to chloramphenicol resistance in S pneumoniae. Chloramphenicol acetyltransferase is encoded by a cat gene identical to the cat gene from the Staphylococcus aureus plasmid, pC194. Tetracycline resistance occurs through ribosomal protection encoded by the genes tet(M) and tet(O). It is possible that the Tet(M) and Tet(O) proteins cause tetracycline to be released from the ribosome, although the precise mechanism remains unclear. Resistance to trimethoprim is mediated through a single amino acid substitution in the chromosomal dihydrofolate reductase gene of S pneumoniae, which is thought to disrupt the bond with trimethoprim without affecting the action of the dihydrofolate reductase. Sulphonamide resistance appears to result from repetitions of one or two amino acids in the chromosomal dihydropteroate synthase. Although resistance exists to nearly all antimicrobial agents used in the treatment of S pneumoniae infections, ongoing research into new or alternative therapies is encouraging.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10501313

Source DB:  PubMed          Journal:  Semin Respir Infect        ISSN: 0882-0546


  13 in total

Review 1.  Molecular detection of antimicrobial resistance.

Authors:  A C Fluit; M R Visser; F J Schmitz
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 2.  Antibiotic use and emerging resistance: how can resource-limited countries turn the tide?

Authors:  Lisa M Bebell; Anthony N Muiru
Journal:  Glob Heart       Date:  2014-10-31

Review 3.  Antimicrobial Therapy in Community-Acquired Pneumonia in Children.

Authors:  Samriti Gupta; Rakesh Lodha; S K Kabra
Journal:  Curr Infect Dis Rep       Date:  2018-09-20       Impact factor: 3.725

4.  Pneumonia Due to Drug-Resistant Streptococcus pneumoniae.

Authors:  Sadao Jinno; Michael R Jacobs
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

5.  Macrolide efflux in Streptococcus pneumoniae is mediated by a dual efflux pump (mel and mef) and is erythromycin inducible.

Authors:  Karita D Ambrose; Rebecca Nisbet; David S Stephens
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

6.  Oropharyngeal colonization by Streptococcus pneumoniae among HIV-infected adults in Uganda: assessing prevalence and antimicrobial susceptibility.

Authors:  David B Blossom; Grace Namayanja-Kaye; Joan Nankya-Mutyoba; John B Mukasa; Henry Bakka; Sandra Rwambuya; Anne Windau; Saralee Bajaksouzian; Courtney J Walker; Moses L Joloba; Cissy Kityo; Peter Mugyenyi; Christopher C Whalen; Michael R Jacobs; Robert A Salata
Journal:  Int J Infect Dis       Date:  2006-09-25       Impact factor: 3.623

Review 7.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Macrolides: A Canadian Infectious Disease Society position paper.

Authors:  S McKenna; G Evans
Journal:  Can J Infect Dis       Date:  2001-07

9.  Antimicrobial use and antimicrobial resistance: a population perspective.

Authors:  Marc Lipsitch; Matthew H Samore
Journal:  Emerg Infect Dis       Date:  2002-04       Impact factor: 6.883

10.  Pilot study of the genetic diversity of the pneumococcal nasopharyngeal flora among children attending day care centers.

Authors:  Raquel Sá-Leão; Alexander Tomasz; Ilda Santos Sanches; Hermínia de Lencastre
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.